Yelak Biru/LinkedIn
Mar 17, 2025, 16:30
Yelak Biru: Ongoing development of novel drugs and innovative combinations is key to pursuing a cure
Yelak Biru, President and Chief Executive Officer of International Myeloma Foundation, shared a post on X a paper by Susan Bal published in The Lancet Haematology:
“Monumen-TAL progress in the treatment of relapsed multiple myeloma – Ongoing drug development of novel agents and deployment of innovative combinations remains paramount in chasing the elusive cure.”
“Monumen-TAL progress in the treatment of relapsed multiple myeloma”
Author: Susan Bal.
More posts featuring Yelak Biru.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:45
May 29, 2025, 17:39
May 29, 2025, 17:28
May 29, 2025, 16:50